User:ChrisMisu/Inflation Reduction Act

Article body
One of the most consequential aspects of this act is the increased negotiating power granted to Medicare. Before the enactment of the Inflation Reduction Act, Medicare was notably restricted in its ability to negotiate drug prices directly with pharmaceutical companies. This limitation often resulted in higher costs for both the program and its beneficiaries. With the new rule, Medicare now engages directly with drug manufacturers, aiming to secure more favorable pricing agreements. This development has the potential to significantly alter the landscape of drug pricing, especially for high-cost medications under Medicare Part D.